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Abstract
Warm antibody autoimmune hemolytic anemia is due to the presence of warm agglutinins that react
with protein antigens on the surface of red blood cells causing premature destruction of circulating
red blood cells. We report the first case of concurrent reactive arthritis, Graves’ disease, and
autoimmune hemolytic anemia. A 40-year-old man with reactive arthritis, Graves’ disease, type 2
diabetes mellitus, mitral valve prolapse, and Gilbert’s disease presented with a one month history of
jaundice, fatigue, and black stools. After diagnosis of warm autoimmune hemolytic anemia, the patient
was started on prednisone 1 mg/kg with rapid improvement in his anemia and jaundice. Our subject’s
mother and possibly his maternal grandmother also had autoimmune hemolytic anemia, which raises
the possibility of hereditary autoimmune hemolytic anemia, a rarely reported condition.
Introduction
Autoimmune hemolytic anemia is occasionally reported
in patients with other autoimmune illnesses, most
commonly systemic lupus erythematosis, rheumatoid
arthritis, scleroderma, and ulcerative colitis [1]. There are
at least 10 case reports of autoimmune hemolytic anemia
associated with hyperthyroidism [2-11], and 1 report of
autoimmune hemolytic anemia associated with reactive
arthritis [12]. However, a Medline search reveals no
previous reports of concurrent reactive arthritis, hyper-
thyroidism, andautoimmunehemolytic anemia.We report
the case of a 40-year-old man who developed severe warm
autoimmune hemolytic anemia while under treatment for
both Graves’ disease and reactive arthritis. Our subject’s
mother and possibly his maternal grandmother also had
autoimmune hemolytic anemia, which raises the possibi-
lity of hereditary autoimmune hemolytic anemia, a rarely
reported condition [13-16].
Case presentation
A 40-year-old Caucasian American man with reactive
arthritis, Graves’ disease, type 2 diabetes mellitus, mitral
valve prolapse, and Gilbert’s disease was admitted with
one month of progressive jaundice, fatigue, lightheaded-
ness, and exertional dyspnea. He also described dark urine
(“the color of raspberry iced tea”) and dark brown to black
stools. He denied fevers or chills, but gave a long history of
night sweats and occasional diarrhea, which he ascribed to
his medications. He had no history of blood transfusions,
prior hepatitis, alcohol use, intravenous drug use, or
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tattoos, and he did not use herbal medications or
supplements. He had recently come to Cleveland to help
care for his father, who had stage IV colon cancer. His
mother had been diagnosed with autoimmune hemolytic
anemia at the age of 40; she was treated with corticoster-
oids and eventually required splenectomy. His maternal
grandmother also had anemia and jaundice, although the
patient was not aware of the cause. His medications were
etanercept, metformin, pioglitazone, methimazole, niacin,
and aspirin. He had stopped the pioglitazone and
metformin more than one month prior to admission
(before the onset of jaundice) on the advice of an
endocrinologist. He had been diagnosed with reactive
arthritis about 10 years before admission, and had been
treated with etanercept for the previous 8 years. His
Graves’ disease had been diagnosed 18 months before
admission, and treated over that time with methimazole.
Physical examination revealed a calm, well-nourished
man with scleral icterus and generalized jaundice. Blood
pressure was 130/76, heart rate 102/min., respiratory rate
16/min, temperature 97.7F. There was no cervical,
supraclavicular, epitrochlear, axillary, or inguinal lympha-
denopathy. The thyroid gland was not enlarged or tender,
and there was no proptosis, lid-lag, or tremor. The lungs
were clear and the heart rhythm was regular without
murmur, click, or gallop. The abdomen was soft and non-
tender, with the liver edge palpable 2 cm below the right
costal margin; the spleen was not palpable. A vesiculo-
bullous rash was seen on the plantar aspect of the right
foot.
Laboratory tests were significant for hemoglobin 5.8 g/dL,
hematocrit 18.7%, MCV 107.5, platelet count 231,000,
WBC count 9,800, reticulocyte count 23.4%, Bilirubin
13.6 (direct 0.6), LDH 369, and haptoglobin <6. Hepatitis
A, B, and C serologies, antinuclear antibody, antimicro-
somal antibody, D-dimer, cold agglutinins, cryoglobulins,
and HIV test were negative. The fibrinogen was normal at
342. The INR was 0.8 and the partial thromboplastin time
was 26.4. The peripheral smear showed spherocytes and
bite cells, with no schistocytes, helmet cells, spur cells,
sickle cells, or teardrop cells. The differential was 54.1%
neutrophils, 35.6% lymphocytes, 8.3% monocytes, 1.7%
eosinophils, and 0.3% basophils. Direct antiglobulin test
(DAT) was + for anti IgG and negative for anti-C3. The
indirect antiglobulin test was negative. The G6PD level
was normal. TSH was 1.067.
Lumbar spine X-rays showed ankylosis of the sacroiliac
joints. Computed tomographic scan of the chest, abdo-
men and pelvis showed probable enlarged thymus in the
anterior mediastinum, a mildly enlarged spleen, and tiny
bilateral renal and hepatic hypodensities too small to be
characterized.
The patient was started on prednisone 1 mg/kg with rapid
improvement in his anemia and jaundice. 11 days after
admission his hemoglobin has improved to 10.0 g/dL.
29 days after admission, the hemoglobin was 14.7 and the
bilirubin had decreased to 3.6 mg/dL. The prednisone was
tapered off over 3 months with continued stable hemo-
globin levels and no evidence of recurrent hemolysis.
Discussion
Hemolytic anemia is caused by premature destruction of
circulating red blood cells. It can be intravascular, as in
microangiopathy, infections, transfusion reactions, and
paroxysmal cold hemoglobinuria, or extravascular, as in
enzyme deficiencies, membranopathies, hemoglobino-
pathies, drug reactions, and most autoimmune hemolytic
anemias.
In this case, the elevated LDH and indirect bilirubin, low
haptoglobin, and high reticulocyte count all were con-
sistent with hemolysis. There was no fever, leukocytosis, or
pertinent travel history to suggest malaria or babesiosis,
and there was no evidence of spider or insect bites. The
patient did not have a history of chronic anemia, which
was against the diagnosis of hereditary spherocytosis. The
normal fibrinogen, negative D-dimer, and absence of
schistocytes on peripheral smear ruled out a microangio-
pathic process. A normal G6PD level, obtained after the
acute phase of the illness, eliminated G6PD deficiency as a
possibility. The DAT revealed an anti-IgG antibody on the
RBC’s, consistent with either a warm autoimmune
hemolytic anemia (WAIHA) or a drug-induced hemolytic
anemia (DIHA). There are 4 case reports of metformin-
induced hemolytic anemia [17], but our patient had
stopped metformin at least a month before his symptoms
developed, so this was very unlikely. There is one reported
case of a patient with rheumatoid arthritis who developed
cold agglutinin disease during etanercept treatment [18],
but cold agglutinin disease is associated with IgM
antibodies and typically causes only mild hemolysis. Our
patient’s cold agglutinin screen was negative. None of his
other medications have been reported to cause hemolytic
anemia. The leading diagnosis was therefore WAIHA. Most
cases of WAIHA are idiopathic, but secondary causes can
include viral infections, autoimmune disorders (particu-
larly SLE, RA, UC, and scleroderma), immune system
malignancies (most commonly CLL), AIDS and other
immunodeficiency disorders, and various non-lymphoid
neoplasms. The work-up for secondary causes was negative
with the exception of the CT scan findings of thymus
enlargement, mild splenomegaly, and multiple sub-
centimeter (ranging 5 to 9 mm) hypodensities in the
liver and kidney of uncertain significance. WAIHA often
precedes the development of lymphoid malignancies,
sometimes by several months; a repeat CT scan is planned
in 2-3 months to reassess the abnormalities.
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Graves’ disease is associated in some patients with
autoimmune dysfunction of multiple organs, including
pernicious anemia, type 1 diabetes mellitus, autoimmune
adrenal insufficiency, vitiligo, systemic sclerosis, myasthe-
nia gravis, Sjogren’s syndrome, systemic lupus erythema-
tosis, and rheumatoid arthritis. Multiple cases of
autoimmune hemolytic anemia associated with
hyperthyroidism have been reported. In Graves’ disease,
IgG type autoantibodies bind to the thyroid cell and
activate the thyroid stimulating hormone receptor, which
increases thyroid metabolic activity. In one case of
hyperthyroidism with AIHA, treatment of hyperthyroid-
ism with propylthiouracil not only restored euthyroidism
but ameliorated the hemolytic anemia as well, without use
of corticosteroids or blood transfusions [8]. The authors
speculate that the hyperdynamic circulatory state in
hyperthyroidism might accelerate hemolysis in antibody-
coated red blood cells. Thomson et al. describe a patient
who developed Graves’ disease during long-term immu-
nosuppressive therapy for acquired autoimmune hemo-
lytic anemia [10]. Thomson’s conclusion was that the IgG
type immunoglobulins that cause Graves’ disease can
develop even in the setting of long-term immunosuppres-
sive treatment. At the time he developed WAIHA, our
patient was clinically and chemically euthyroid after
18 months of propylthiouracil treatment. He had also
been on immunosuppressive treatment with the tumor
necrosis factor-inhibitor etanercept for several years,
with good control of his reactive arthritis symptoms. The
WAIHA seems not to have developed in response to a
flare-up of either condition.
Reactive arthritis occurs after primary extraarticular infec-
tions, either enteric or sexually transmitted, and is
characterized by the presence of bacterial antigen and/or
viable but non-culturable bacteria that persist within the
joint. HLA-B27 is present in 70-80% of patients with
reactive arthritis, and HLA-B27 increases the risk of reactive
arthritis by 25-fold. Although there are a number of
known bacterial triggers for development of reactive
arthritis, the precise mechanism of the pathologic host
response is unknown. Possibilities include an HLA-B27
autoantigen, cellular uptake of causative organisms, toll-
like receptors, and chemokine involvement [19]. Graves’
disease has been associated with a variety of infectious
agents, including Yersinia enterocolitica, which is also one of
the bacteria known to cause reactive arthritis [20].
Yersinia enterocolitica has not, however, been reported as
a cause of WAIHA. We were unable to find any prior
case reports of concurrent reactive arthritis and Graves
disease. There is one report of a 30-year-old man in
Papua New Guinea who developed severe hemolytic
anemia (Hb 2.8) in the setting of reactive arthritis with
urethritis, conjunctivitis, and keratoderma blenorrhagica
[12]. Although a DAT was not reported, the author
argued that the hemolysis was autoimmune because
malaria and hypersplenism were excluded, and the
anemia resolved with methotrexate and prednisolone
treatment.
There are only a few case reports of hereditary auto-
immune hemolytic anemia [13-16]. The paucity of reports
and the sporadic pattern of involvement suggests that
familial occurrence of AIHA is likely to be coincidental,
although the sharing of HLA antigens 1 and 8 in a report of
two affected sisters might argue for a genetic susceptibility
in some cases [15]. It has been postulated that auto-
immune diseases are a “mosaic” of genetic, immune,
hormonal, and environmental factors. Genetic causes may
include human leukocyte antigen (HLA) genes, non-HLA
immune-regulatory or tissue-specific genes, and
genetically-determined selective IgA deficiency [21]. Envir-
onmental factors may include infection, with Yersinia as
a possibility, or the use of medications including long-
term cytokine suppression with etanercept. A combination
of genetic and environmental factors might have con-
tributed to this patient’s development of multiple auto-
immune diseases.
Conclusion
We report the first case of concurrent reactive arthritis,
Graves’ disease, and autoimmune hemolytic anemia.
Yersinia enterocolitica infection could theoretically cause
both reactive arthritis and Graves’ disease, although we
cannot prove this connection in our patient’s case. It is not
clear whether the autoimmune hemolysis was coinciden-
tal or related to an underlying condition that predisposed
this patient to multiple autoimmune diseases. The family
history of autoimmune hemolysis suggests the possibility
of an inherited predisposition.
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